首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1809440

BRCA市場規模·對象患者族群·競爭情形·市場預測 (～2034年)

BRCA Market Size, Target Population, Competitive Landscape & Market Forecast - 2034

出版日期: 2025年09月01日 | 出版商:

DelveInsight | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

本報告詳細介紹了美國、歐盟四國（德國、法國、義大利、西班牙）、英國和日本的 BRCA 藥物的市場規模、目標患者群體、競爭格局及未來市場趨勢。

本報告深入分析了目前的 BRCA 治療方案、已核准（如有）和新興的 BRCA 藥物、每種藥物的市場份額以及 BRCA 患者群體。該報告還分析了 2020 年至 2034 年七大市場（美國、歐盟四國、英國和日本）按藥物和適應症劃分的市場規模（包括當前和預測數據）。本報告也探討了目前未滿足的需求和挑戰、新型治療方案如何融入治療體系，以及新型 BRCA 藥物在可及性和接受度方面的區域差異。該報告還深入分析了 BRCA 藥物的定價和報銷情況，旨在評估市場潛力並尋找最佳商機。

目標地區

美國
歐盟四國（德國、法國、義大利、西班牙）、英國
日本

研究週期：2020-2034

研究範圍：

關鍵事件的選擇、摘要整理、目標患者群體、流行病學和市場預測、患者治療途徑以及各種生物標誌物檢測率的信息
全面描述已上市和新興療法，並深入了解 BRCA 治療的目標族群
詳細回顧 BRCA 市場，包括歷史和預測市場規模、按療法劃分的市場份額、詳細的假設和方法論依據
SWOT 分析、專家/KOL 意見和治療方法選擇了解這些趨勢可提供策略優勢，並有助於塑造和推動第七大市場 (MM) 的 BRCA 市場。
治療藥物和適應症劃分的抑制劑市場規模

BRCA報告主要的優勢

11 年市場預測
700 萬市場覆蓋率
已上市及新興療法的競爭格局
BRCA 療法可涵蓋的患者總數
藥物採用與主要市場預測假設
已獲批准和計劃內療法概況
醫生觀點/KOL 意見
生物標記檢測與病患照護途徑
定性分析（SWOT 分析和分析師觀點）
依治療藥物和適應症劃分的市場規模
現有與未來的市場機遇
未滿足的需求

常見問題

2020 年的整體市場規模、各治療藥物的市場規模、市佔率分佈為何？ 2034 年又會如何？ BRCA 市場成長的驅動因素有哪些？
到 2034 年，哪一種 KRAS 抑制劑的貢獻最大？
BRCA 的市場進入和報銷情況如何？
各地區的價格動態如何？
市場驅動因素、障礙和未來機會如何影響市場動態和相關趨勢的分析？
為了克服目前市售療法的局限性，正在開發哪些最新的新型治療藥物、標靶、作用機制和技術？
在現實場景中，基於病患治療偏好的可接受性如何？

主要調查結果
市場預測
主要的前提條件
主要7個國家的整體市場規模
- 市場規模:各治療藥物
- 市場規模:各適應症
美國
- 市場規模
- 市場規模:各治療藥物
EU4·英國
- 市場規模
- 市場規模:各治療藥物
日本
- 市場規模
- 市場規模:各治療藥物

第11章未滿足需求

第12章 SWOT分析

第13章 KOL的見解

第14章市場進入與償付

美國
EU4·英國
- 德國
- 法國
- 義大利
- 西班牙
- 英國
日本

第15章附錄

第16章 DelveInsight的功能

第17章免責聲明

第18章關於DelveInsight

簡介目錄圖表

Product Code: DIIM0016

DelveInsight's "BRCA Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report delivers an in-depth understanding of BRCA, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

The BRCA market report provides insights around existing treatment practices in patients with BRCA, approved (if any) and emerging BRCA, market share of individual therapies, patient pool eligible for treatment with BRCA, along with current and forecasted 7MM BRCA market size from 2020-2034 by therapies and by indication. The report also covers current unmet needs and challenges while incorporating new classes in treatment paradigm, variations in accessibility and acceptability of new BRCA in different geographies, along with insights on BRCA pricing reimbursements to curate the best opportunities and assess the market's potential.

Geography Covered:

The United States
EU4 (Germany, France, Italy, and Spain), and the UK
Japan

Study Period: 2020-2034

BRCA Overview

This segment will provide detailed information beginning with the inhibitor journey from discovery of the mutation or protein expression to its entry into clinical development followed by its upcoming commercial potential. This segment will dive into the different indications for which the inhibitor is being developed for, which would further give insights on the potential addressable patient population. Moreover, this segment will also give a brief overview around the existing treatment paradigm of the target indications.

BRCA in Clinical Practice

This section will give in depth information about the existing local and systemic options in the current treatment paradigm of all the potential indications, in which most of the pharmaceutical companies are actively evaluating their inhibitors. Potential of the emerging BRCA in changing the current clinical practice guidelines is crucial to analyze especially when it comes to real world scenario.

It will also include the relevance and importance of incorporation of biomarker testing at varying stages of the disease. It is also important to understand that implementing such tests in routine clinical practice is not uniform in different countries due to issues such as cost, accessibility, reimbursement and non-recommendation in guidelines.

BRCA Drug Chapters

The drug chapter segment of the BRCA report encloses a detailed analysis of marketed therapies and late-stage (Phase III and Phase II) therapies. It also helps understand the BRCA clinical trial details, pharmacological action, agreements and collaborations related to BRCA, their approval timelines, patent details, advantages and disadvantages, latest news and press releases.

BRCA Marketed Drugs

The BRCA marketed drug section will provide detailed drug profiles of already approved therapies. Information around clinical development activities, launch timing, regulatory milestones along with safety and efficacy data of the therapy will be included.

BRCA Emerging Drugs

Apart from a comprehensive BRCA competitive landscape in tabular form, the emerging KRAS Inhibitor chapters provides the product details and other development activities of the emerging BRCA under the late and mid-stage of clinical development for various indications.

Drug Class Insights

The Drug Class Insights section will provide comprehensive information on BRCA as a class. This will include a broad overview of the class and its role in treating specific conditions. Insights may cover the historical clinical development of BRCA, their mechanism of action, their subtypes and future commercial prospects. Additionally, the section will provide detailed information about current trends, challenges, and future prospects for this class of drugs.

BRCA Market Outlook

This section will include details on changing BRCA market dynamics post initiation of clinical development activities of the inhibitor. It will also provide a detailed summary and comparison of all the therapies being developed by leading players in this space. This section will highlight the advantages of one therapy over the other after assessment based on parameters such as data availability in the form of safety and efficacy, number of patients enrolled in each trial, and trial's inclusion criteria. There will be a Key focus on the importance of development and need for the commercial success of these targeted therapies to achieve treatment goals that physicians and patients are looking for. It will also sum up all the early stage players active in this space.

BRCA Drugs Uptake

This section focuses on the uptake rate of potential BRCA already launched and expected to be launched in the market during 2020-2034, which depends on the competitive landscape, safety, efficacy data, and order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

BRCA Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III and Phase II stages. It also analyzes key players involved in developing targeted therapeutics.

BRCA Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for BRCA.

KOL Views

To keep up with current and future market trends, we incorporate Key physicians, Therapy Area Researcher's, and other Industry Experts' opinions working in the domain through primary research to fill in the data gaps and validate our secondary research. 25+ Key Opinion Leaders (KOLs) were contacted for insights on BRCA' incorporation in the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along with challenges related to accessibility.

Qualitative Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Analyst views. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst's discretion and assessment of the cost analysis and existing and evolving treatment landscape.

Market Access and Reimbursement

This section will include insights around the standard HTA pricing, recent reformations in 2024 and modifications in reimbursement process in the 7MM. For example, In the United States, a multi payer model exists when it comes to drug pricing regime, which is currently undergoing significant changes, with recent federal legislation, such as the Prescription Drug Pricing Reform provisions of the Inflation Reduction Act, significantly altering the pricing regime under certain federal programs. Whereas in Germany, the market access differs from the systems followed in many other countries as no pricing and reimbursement approval is required during launch of a new therapy.

Moreover, this section will also provide details on reimbursement of approved therapy, if any.

Scope of the Report:

The report covers a segment of key events, an executive summary, target patient pool, epidemiology and market forecasts, information around patient journey and varying biomarker testing rates
Additionally, an all-inclusive account of the current and emerging therapies drug chapters, insights on BRCA addressable patient pool
A detailed review of the BRCA market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report
The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, and treatment preferences that help in shaping and driving the 7MM BRCA market.
Market Size of Inhibitors by therapies and indication will be provided

BRCA Report Key Strengths

11 Years BRCA Market Forecast
The 7MM Coverage
BRCA Competitive Landscape of current and emerging therapies
BRCA Total Addressable patient population
Drugs Uptake and Key Market Forecast Assumptions
Approved and Emerging therapy Profiles
Physician's perspectives/KOL opinions
Biomarker testing and Patient journey
Qualitative Analysis (SWOT and Analyst Views)
BRCA Market Size by therapy and indication
Existing and Future Market Opportunity
Unmet Needs

FAQs:

What was the BRCA total market size, the market size by therapies, market share (%) distribution in 2020, and what would it look like by 2034? What are the contributing factors for BRCA market growth?
Which KRAS Inhibitor is going to be the largest contributor by 2034?
What is the market access and reimbursement scenario of BRCA?
What are the pricing variations among different geographies?
How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
Patient acceptability in terms of preferred treatment options as per real-world scenarios?

Reasons to Buy:

The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the BRCA Market.
Understand the existing BRCA market opportunities and future trends in varying geographies
Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
To understand Key Opinion Leaders' perspectives around the accessibility and acceptability of emerging treatment options along with unmet need of current therapies
Details on report methodology, top indications covered, market assumptions, patient journey and KOLs to strengthen the pharmaceutical companies' development and launch strategy.

1. Key Insights

2. Report Introduction

3. Executive Summary of BRCA

4. Key Events

5. BRCA Market Overview At A Glance

5.1. Market Share (%) Distribution of BRCA By Therapy in 2023
5.2. Market Share (%) Distribution of BRCA By Therapy in 2034

6. Background And Overview

7. Target Population

8. BRCA Marketed Drugs

8.1. Key Competitors
8.2. Company 1: Product 1
- 8.2.1. Product Description
- 8.2.2. Regulatory Milestones
- 8.2.3. Other Developmental Activities
- 8.2.4. Ongoing Clinical Development
- 8.2.5. Safety and Efficacy
8.3. Company 2: Product 2
- 8.3.1. Product Description
- 8.3.2. Regulatory Milestones
- 8.3.3. Other Developmental Activities
- 8.3.4. Ongoing Clinical Development
- 8.3.5. Safety and Efficacy

9. BRCA Emerging Drugs

9.1. Key Competitors
9.2. Company 1: Product 1
- 9.2.1. Product Description
- 9.2.2. Other Development Activities
- 9.2.3. Clinical Development
  - 9.2.3.1. Clinical Trials Information
- 9.2.4. Safety and Efficacy
9.3. Company 2: Product 2
- 9.3.1. Product Description
- 9.3.2. Other Development Activities
- 9.3.3. Clinical Development
  - 9.3.3.1. Clinical Trials Information
- 9.3.4. Safety and Efficacy

10. BRCA: The 7MM Analysis

10.1. Key Findings
10.2. Market Outlook
10.3. Key Market Forecast Assumptions
10.4. Total Market Size of BRCA in the 7MM
- 10.4.1. Market Size of BRCA By Therapies In the 7MM
- 10.4.2. Market Size of BRCA By Indication In the 7MM
10.6. United States Market
- 10.6.1. Total Market Size of BRCA in the United States
- 10.6.2. Market Size of BRCA By Therapies in the United States
10.7. EU4 and the UK Market
- 10.7.1. Total Market Size of BRCA in EU4 and the UK
- 10.7.2. Market Size of BRCA By Therapies in EU4 and the UK
10.8. Japan Market
- 10.8.1. Total Market Size of BRCA in Japan
- 10.8.2. Market Size of BRCA By Therapies in Japan

11. Unmet Needs

12. SWOT Analysis

13. KOL Views

14. Market Access and Reimbursement

14.1. United States
- 14.1.1. Centre for Medicare & Medicaid Services (CMS)
14.2. EU4 and the UK
- 14.2.1. Germany
- 14.2.2. France
- 14.2.3. Italy
- 14.2.4. Spain
- 14.2.5. United Kingdom
14.3. Japan
- 14.3.1. MHLW